MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Human volunteers will soon begin receiving an HIV vaccine that contains an adjuvant developed in Irvine’s lab, which helps to boost B cell responses to the vaccine.